AOH1996 NEW
| Price | $60 | $147 | $228 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-15 |
Product Details
| Product Name: AOH1996 | CAS No.: 2089314-64-5 |
| Purity: 98.63% | Supply Ability: 10g |
| Release date: 2026/07/15 |
Product Introduction
Bioactivity
| Name | AOH1996 |
| Description | AOH1996 belongs to small molecule inhibitors and is a PCNA ligand targeting transcription-replication conflicts, with oral activity, metabolic stability, and tumor selectivity. This compound induces transcription-dependent DNA double-strand breaks and apoptosis, and is used for antitumor therapy. |
| In vitro | Methods: Seven AML cell lines and primary CD34+CD38- leukemic stem cells (LSC) were treated with AOH1996 at concentrations of 0.5–1 μM for 24 hours, and cell proliferation, apoptosis, and colony formation assays were performed. Results: AOH1996 dose-dependently inhibited proliferation and colony formation of AML cells and LSC, induced apoptosis, and had no significant effect on normal CD34+CD38- hematopoietic stem cells.[1] |
| In vivo | Methods: Human primary AML cells were transplanted into Es1(ko)SCID mice, and 7 days later, AOH1996 (100 mg/kg) was administered by oral gavage twice daily for 3 weeks. Results: AOH1996 significantly reduced leukemia burden in peripheral blood and spleen, and extended median survival from 35 days to 50 days; secondary transplantation confirmed reduced LSC burden, with survival extended from 30 days to 42 days.[1] |
| Storage | Keep away from direct sunlight, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (586.22 mM), Sonication is recommended. |
| Keywords | PCNA | DNA | apoptosis | AOH-1996 | AOH1996 | AOH 1996 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3420.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
Fuzhou Lista Biotechnology Co.,Ltd
|
2024-07-17 | |||
| $1.00 |
VIP3Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2026-08-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY